ALZHEIMER’S BREAKTHROUGH: Experimental Biogen Drug Shows Early Promise in Slowing Disease
An experimental Alzheimer’s drug developed by Biogen showed encouraging early results in slowing the disease by targeting the brain protein tau, offering a different approach from current treatments. Researchers said the findings are promising, but larger clinical trials are needed to confirm the drug’s effectiveness.